19Dec
As its COVID-19 Vaccine Nears Finalization, AstraZeneca Announces Deal to Buy Alexion for $39 Billion
AstraZeneca, the British-Swedish multinational pharmaceutical company currently collaborating with the University of Oxford on a COVID-19 vaccine, will purchase Alexion Pharmaceuticals for $39 billion. The transaction, which awaits approval by shareholders and regulators, is the largest purchase by a health care company this year and is expected to close in the third quarter of 2021. Alexion was founded in 1992 and is headquartered in Boston but has a global presence. It is known for its...
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
If you’ve received a PAGA notice, you can count yourself as one of several thousands of California ...
Read More >
In 2019, we have seen the worldwide antitrust enforcement trend continue, keeping even Silicon Valle...
Read More >
The US Senate yesterday passed a package of tax extenders as part of the year-end appropriations act...
Read More >
As anticipated, in one of the last decisions before the end of Member McFerran’s term, the NLRB iss...
Read More >
As a retirement plan provider, you need to stand out in the crowd be- cause of the competitive natur...
Read More >
- On April 17, 2020, the CMA provisionally cleared Amazon’s investment in Deliveroo in light of the...
Read More >